Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00268788|
Recruitment Status : Completed
First Posted : December 22, 2005
Last Update Posted : February 21, 2008
The purpose of this study is to evaluate the effect of subcutaneous administration of immunoglobulin compared to intravenous treatment, for multifocal motor neuropathy
NB. ONLY RECRUITING FROM DENMARK
|Condition or disease||Intervention/treatment||Phase|
|Multifocal Motor Neuropathy||Drug: Subcutaneous immunoglobulin Drug: Intravenous immunoglobulin||Phase 2|
Introduction Intravenous immunoglobulin (IVIG) treatment is the only established treatment modality in Multifocal Motor Neuropathy (MMN). In order to maintain neuromuscular performance patients require lifelong treatment. Hospital-based treatments have high cost and inconveniences to patients, particularly in chronic disorders. Immunoglobulin preparations are now available for subcutaneous use as IgG replacement therapy. The safety and efficacy of subcutaneous infusion is reported to be comparable to i.v. preparations, and has been applied successfully in other autoimmune disorders. However patients with MMN have not previously been treated with subcutaneous immunoglobulin.
Subcutaneous immunoglobulin treatment is efficacious and safe with less patient inconvenience.
Isokinetic muscle strength at the end of treatment A vs B (subcutaneous vs i.v.)
Medical research council score (MRC-score), 9-hole peg test, 10m walking, Nerve conduction parameters, SF-36.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||A Controlled Cross-Over Trial of Subcutaneous Versus Intravenous Immunoglobulin for Multifocal Motor Neuropathy|
|Study Start Date :||August 2005|
|Actual Primary Completion Date :||February 2008|
|Actual Study Completion Date :||February 2008|
Active Comparator: 1
Subcutaneous Ig given twice a week.
Drug: Subcutaneous immunoglobulin
Individually dosed, given twice a week.
Other Name: Subcuvia
Active Comparator: 2
Drug: Intravenous immunoglobulin
Individual dose and frequency
Other Name: Endobulin
- Isokinetic muscle strength at the three most affected muscle groups. [ Time Frame: At the end of each arm of the crossover study ]
- Medical research council score (MRC-score), [ Time Frame: At the end of each treatment arm of the crossover study ]
- 9-hole peg test, [ Time Frame: At the end of each treatment arm of the crossover study ]
- 10m walking, [ Time Frame: At the end of each treatment arm of the crossover study ]
- Nerve conduction parameters, [ Time Frame: At the end of each treatment arm of the crossover study ]
- SF-36 [ Time Frame: At the end of each treatment arm of the crossover study ]
- Adverse effects [ Time Frame: During each treatment arm of the crossover study ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00268788
|Aarhus University Hospital, Department of Neyrology|
|Principal Investigator:||Henning Andersen, MD, DMSc||Aarhus University Hospital, Aarhus, Denmark|
|Study Chair:||Johannes Jakobsen, Professor||Aarhus University Hospital|